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Abstract
Background: Several epidemiological studies have shown that cannabis; the most widely used illegal drug in the 
world, is associated with schizophrenia spectrum disorders (SSD).
Aims: To assess the characteristics of cannabis use and its association with SSD in a cohort of psychiatrically ill patients 
and discuss the implications for policy development
Methods: This is a retrospective analytical study of a cohort of psychiatric patients who received treatment in the 
psychiatry unit of the Provincial General Hospital, Ratnapura, Sri Lanka over five years (2000 - 2004). The schizophrenia 
spectrum disorders defined in this article include schizophrenia and the schizoaffective disorders.
Results: A total of 3644 patient records were analyzed. The percentage of self reported life time cannabis (LTC) use was 
2.83% (103, all males). Sixteen percent (576) of the total cohort was diagnosed with SSD by 2009. Male sex and LTC use 
were significantly associated with SSD (p < 0.01 and 0.001 respectively). In the majority (91.5%), cannabis use preceded 
the diagnosis. There were 17(16.5%) patients diagnosed as cannabis induced psychosis and 7 (41.2%) of them were 
subsequently diagnosed as SSD. This group was significantly more likely to have had a past psychiatric consultation, 
but other demographic and clinical correlates did not differ from the rest of the LTC users.
Conclusions: Self reported LTC use was strongly associated with being diagnosed with SSD. However we could not 
identify a particular subgroup of users that are at increased risk to recommend targeted primary prophylaxis. The policy 
implications of this observation are discussed.
Background
The plant Cannabis sativa grows in temperate and tropi-
cal climates. Its seeds, flowering tops, leaves and stalks
contain a cocktail of chemicals termed cannabinoids,
some of which (e.g.- Δ9 tetrahydrocannabinol) cause psy-
choactive manifestations following ingestion or inhala-
tion of smoke[1]. It is considered to be the most widely
used illegal drug in the world and 4% of world's adult
population (160 million) were using cannabis in 2005[2].
This was a 10% increase compared to the estimates in
1995.
The evidence for an association between cannabis use
and schizophrenia spectrum disorders (SSD) was demon-
strated more than 20 years ago [3-5]. The first landmark
longitudinal study demonstrating such a link was pub-
lished in 1987 by Andreasson et al[3]. They showed (in a
15 year follow up of 45,570 Swedish conscripts) a higher
risk of schizophrenia among heavy cannabis users [Rela-
tive risk (RR) - 6.0]. A follow up study of 535 patients
treated for cannabis induced psychotic symptoms in
Denmark observed that 238 (44.5%) of them were subse-
quently treated for schizophrenia spectrum disorders.
Male gender and younger age were associated with an
increased risk for SSD[6]. Arseneault et al[7] have also
observed a higher risk of schizophrenia in young canna-
bis users. They analyzed data from a birth cohort in
Dunedin, New Zealand. Younger age of cannabis use (age
15 vs. 18) was associated with a greater risk of schizo-
phrenia and the cannabis users were more likely to be
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symptomatic by age 26 than controls. Still, a majority of
users did not develop psychotic symptoms. Barnes et
al[8] have also shown that male gender and cannabis use
were significantly associated with subsequent schizo-
phrenia and a younger age of onset of illness. They fur-
ther showed that such an association did not exist for
alcohol or any other substance examined (hallucinogens,
stimulants, opiates).
While such observations are made repeatedly, some
questions are left unanswered. One is regarding the
actual mechanism of the association between cannabis
and SSD. Different theories have been proposed each
having its proponents and opponents. They are as fol-
lows: a) cannabis use causes SSD (causal model); b)
patients with SSD are attracted to cannabis use; c) canna-
bis use induces SSD in a minority with background vul-
nerability [9,10]. The theory of background vulnerability
(third hypothesis) has been a point of interest in recent
research [11]. However, the exact nature of this vulnera-
bility is unclear (e.g. genetic, environmental or a combi-
nation of them). On the genetic aspect, a functional
polymorphism of the gene encoding the catechol-O-
methyl transferase (COMT) enzyme (which degrades cat-
echolamines such as dopamine, noradrenaline etc.) has
been of interest. The polymorphism results in two alleles
of high (Val) and low (Met) enzymatic activity. The highly
active variant is hypothesized to cause imbalance in dop-
amine concentrations in prefrontal and mesolimbic areas
resulting in cognitive defects and psychotic phenomena
respectively. One study has shown that those homozy-
gous for Val gene or even carriers of it are more likely to
have psychotic symptoms and a subsequent diagnosis of a
SSD following cannabis use [11]. The influence of envi-
ronmental factors may also be relevant but the evidence
is limited. Compton et al [12,13] have demonstrated that
childhood experiences of physical and sexual abuse were
significantly more in patients with a dual diagnosis of first
episode SSD and cannabis use. However the sample size
in this study was small to come to a valid conclusion.
Another interesting hypothesis that contrasts the theo-
ries supporting an aetiological role of substance use on
schizophrenia needs to be mentioned as well. This theory
was formulated by the repeated observation of a better
premorbid adjustment (less social withdrawal, better peer
relations, socio sexual adjustment and interests) in sub-
stance users and abusers[14]. It was proposed that people
with better premorbid adjustment have an increased risk
of exposure to substance use due to their sociability.
Later, when some of them develop schizophrenia (by an
unrelated process), the stresses of illness may drive them
to have pronounced substance abuse as a maladaptive
coping strategy. Yet an observer (to whom early features
of prodrome are not obvious but the increase in sub-
stance use is) may think that heavy substance use pre-
ceded and hence had an aetiological role in
schizophrenia. The initial studies showing a better pre
morbid adjustment in substance users with psychiatric
illnesses did not differentiate between the substances
used[15,16]. However Arendt et al[14] have demon-
strated a statistically significant better premorbid adjust-
ment among exclusive alcohol abusers and cannabis
abusers with schizophrenia. Still, the number of exclusive
cannabis abusers was small (n-9) in this cohort. Another
fact that favoured this hypothesis was the absence of a
similar observation among stimulant and hallucinogen
abusers and non abusers. The impact of these substances
on neurotransmitter systems had been demonstrated and
it was assumed that the lack of such an association was
due to their (hallucinogens and stimulants) possible aeti-
ological role in psychosis. However since the publication
of these observations in 1992, the impact of cannabinoids
on neurotransmitter systems has also been speculated,
backed by the findings of several experimental neurobio-
logical studies. The current opinion is that modulation of
release of neurotransmitters; dopamine, gamma amino-
butyric acid (GABA) and glutamate by cannabinoids (act-
ing via the cannabinoid receptor 1 in mesolimbic and
mesocortical systems) account for its psychotic manifes-
tations[10]. There is also heterogeneity and contrasting
effects of various cannabinoids in this regard. For exam-
ple, tetrahydrocannabinol (THC) has mainly psychomi-
metic and anxiety enhancing effects while cannabidiol
(another cannabinoid compound) is shown to have anxi-
olytic and antipsychotic properties [17-19].
Another grey area is the diagnosis of 'cannabis induced
psychosis' (CIP) which is sometimes used to refer to the
psychotic manifestations with cannabis. Experimental
studies with THC have shown it to induce both positive
a n d  n e g a t i v e  sym p t o m s  wi t h  c ogn i t i v e  d e fi ci ts  i n  bo t h
healthy individuals and schizophrenic patients [20,21].
However, several clinical studies have shown that the
patients with 'cannabis induced psychosis' and those sub-
sequently diagnosed with schizophrenia demonstrate
more positive symptoms and fewer negative symptoms
[10,22-26]. Some authors doubt the diagnosis of CIP alto-
gether. They argue that it is early onset schizophrenia
[27,28]
Most of the research on cannabis use and its sequelae
are from cohorts in developed countries. There are only a
few recent studies on cannabis use in the South Asian
region and this appears to be the first analytical study on
cannabis use among psychiatric patients in Sri Lanka.
Based on the above observations, this study was
designed to answer several queries;
a) to identify the characteristics of cannabis use in 
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b) to confirm the existence of an association between 
cannabis use and subsequent development of SSD in 
this sample.
c) in the event of finding such an association, to 
explore the evidence with relation to the existing the-
ories on cannabis and SSD.
d) to characterize the impact of environmental and 
other confounding factors on cannabis use and SSD
e) to explore whether CIP patients as a group differed 
from the rest of the cannabis users to justify the 
uniqueness of this diagnosis
f) to recommend policy changes on cannabis use 
based on the findings of the study
Methods
This is a retrospective analytical study of a cohort of psy-
chiatrically ill patients who received treatment in the Pro-
vincial General Hospital, Ratnapura (PGHR), Sri Lanka
over the five years from 2000 Jan 1st to 2004 Dec 31st. The
PGHR and its psychiatry unit cater to the healthcare
needs of approximately 9.4% (1.8 million in 2003) of the
country's population in both urban and rural areas [29].
Furthermore, it was the only center in the district with
inpatient treatment facilities under the supervision of a
consultant psychiatrist during the time period for this
retrospective follow up (2000 - 2004). Therefore it is
likely that a majority of patients with psychiatric symp-
toms came to this unit for treatment as it was the only
option available. The records were analyzed in 2009. At
this point we were able to obtain data over a follow up
period of between 5 and 9 years.
The investigators examined the records of all patients
treated within the specified time period in the psychiatry
unit of PGHR. Each patient seen at clinic or ward is allo-
cated a separate file with a clinic number and all the data
on this patient (clinic visits or admissions) are updated in
the same file over the years. Every patient admitted (or
assessed in the clinic) is seen by two doctors (first
assessed by the attending doctor of the unit and later
reviewed by the consultant psychiatrist). A detailed his-
tory is recorded on the first page of the patient's records.
The same procedure is repeated with each subsequent
admission. Details on psychoactive substance use are
queried from patients as a routine on every admission
and documented. This includes the use of alcohol, nico-
tine and any other common substances of abuse. How-
ever laboratory facilities were not available at that time to
test for serum or urinary levels of narcotics in Ratnapura
(routine or 'on request' testing). Even now, such facilities
are not available and if urine needs to be tested for can-
nabinoids, a sample has to be sent to the capital Colombo
to be tested in a private laboratory at patient's expense.
Therefore, the substance use documented in records was
obtained by self report only. The logistical difficulties
mentioned above prevented independent laboratory con-
firmation of substance use.
All the patient records from 2000 to 2004 were exam-
ined for a history of life time cannabis use and the data of
these patients were extracted to a data sheet. The term
life time cannabis (LTC) use in this paper strictly refers to
self reported LTC use. Data were collected on demogra-
phy, clinical presentation, cannabis use, concurrent sub-
stance use, treatment and follow up details for those
reporting LTC use.
These data were analyzed and compared in several
ways to achieve the objectives cited above. The analysis
was arranged to;
a) compare the prevalence of schizophrenia spectrum 
disorders between the life time cannabis (LTC) user 
group and the non users
b) Analyze the demographic and clinical profile of 
LTC users
c) Comparison of SSD and non SSD patients in LTC 
user group to identify any characteristic features of 
the earlier subgroup
d) Try to establish any unique characteristics of the 
group diagnosed as CIP by
i. comparing them with other LTC users
ii. comparing the CIP patients diagnosed with 
SSD with other SSD patients in the LTC user 
group
e) To summarize the findings to identify an associa-
tion between cannabis use and subsequent develop-
ment of SSD
A clear establishment of the timeline between cannabis
use, onset of psychotic symptoms and diagnosis of SSD
was important to come to valid conclusions. All the
patient records were dated before each entry by the
attending doctors so there was no confusion in establish-
ing the timeline after the patient was registered in the
unit. The date of diagnosis of SSD was established as the
date such a diagnosis was first documented in the patient
records provided there were concurrent documentation
of symptoms keeping with the ICD - 10 (International
Classification of Diseases - 10) diagnostic criteria. The
data extraction sheet had a checklist referring to each
diagnostic criteria of ICD -10 for this purpose. Following
the establishment of the date of diagnosis, any recorded
cannabis use before and after (as mentioned in records)
were noted. However, the formal date of diagnosis does
not necessarily indicate the actual onset of disease. The
'onset' of disease was difficult to establish from clinic
records alone due to missing data and the retrospective
nature of the study. Therefore, we were restricted to
establish the timeline between cannabis use and the diag-
nosis of illness (easier to establish from records) rather
than between cannabis use and the 'onset of illness' (diffi-
cult to establish from records).Rodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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The data were analyzed with SPSS v15 statistical soft-
ware, and significance of associations were calculated
using appropriate statistical tests such as chi square test
and Fisher's exact test. Findings relevant to descriptive
statistics were summarized into proportions and averages
(mean/standard deviation or percentiles) based on the
scales of measurements. Comparison of means was done
with unpaired t test. Ethical clearance for the study was
granted by the ethics review committee of Faculty of
Medicine, University of Colombo.
The schizophrenia spectrum disorders identified in this
article include all classifications of schizophrenia and
schizoaffective disorders. There were no diagnoses in the
LTC user cohort for schizotypal and schizoid personality
disorders. ICD - 10 is the manual used for diagnosis in Sri
Lankan psychiatry units.
Results
Three thousand six hundred and forty four (3644) patient
records (males - 2095, females - 1549) were scrutinized
for evidence of cannabis use. Evidence of LTC use was
found in 103 (2.83%) patients. All patients with a history
of cannabis use were males.
The majority of LTC users belonged to the 21 - 30 age
group (47, 45.6%) and the Sinhalese ethnicity (95, 92.2%).
Fifty four (52.4%) admitted to concurrent alcohol use and
21 (20.4%) to nicotine use. One person had used heroin.
The socio-demographic variables of LTC users are sum-
marized in table 1.
The results are presented under the following subtopics
1. Comparison between LTC user SSD patients and 
non-cannabis-using SSD patients
2. Characteristics of cannabis use in the sample
3. Comparison between SSD patients and non-SSD 
patients in the LTC user group
4. Comparison between patients diagnosed as canna-
bis induced psychosis (CIP) and the rest of the LTC 
user group
5. Comparison between SSD patients in CIP (CIP-
SSD) group and other cannabis using SSD patients
Comparison between LTC user- SSD patients and non 
cannabis using SSD patients
Of the total sample, 576 (15.8%) patients were diagnosed
with a schizophrenia spectrum disorder (SSD) by 2009
[males: 359 (62.3%), females: 217 (37.7%)]. Males were
more likely to be diagnosed with a SSD [RR: 1.22, 95%
confidence interval (CI): 1.04-1.42] (chi square test, df - 1,
χ2 - 6.54, p-0.01). In the LTC user group, 47 (45.6%, all
males) were diagnosed with SSD during follow up (by
2009). Of them, 43 were diagnosed with schizophrenia
and 4 with schizoaffective disorder. This was 8.1% of the
Table 1: Descriptive statistics of the socio-demographic variables 
of patients with life time cannabis (LTC) use
Variable Number Percentage (%)
Sex
Male 103 100
Female 0 0
Age (years)
0 - 10 0 0.0
11 - 20 10 9.7
21 - 30 47 45.6
31 - 40 22 21.4
41 - 50 9 8.7
51 - 60 6 5.8
61 - 70 1 1.0
Unknown 8 7.8
Civil status
Married 31 30.1
Unmarried 46 44.7
Unknown 26 25.2
Level of education
No formal education 4 3.9
Primary education 31 30.1
Secondary education 44 42.7
Tertiary education 0 0.0
Unknown 24 23.3Rodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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total sample with SSD and 13.1% of the males with SSD
(table 2). The relative risk of a LTC user to have SSD was
3.05 (95% CI: 2.44- 3.82) compared to a non user and
when males alone were considered, it was 2.91 (95% CI:
2.31- 3.68). Both these associations were statistically sig-
nificant (chi square test, df - 1, χ2 - 70.58, p < 0.0001), (chi
square test, df - 1, χ2 - 80.01, p < 0.0001).
Characteristics of cannabis use in the sample
The characteristics of cannabis use in the sample are
summarized in table 3. There were four first time users
with psychotic symptoms and two (50%) of them were
diagnosed with SSD during follow up. At the time of first
admission, a significant percentage (38, 63.3%) had used
cannabis for more than 1 year (the duration of use was
recorded in only 60 of the 103 patients). The number of
short duration users (less than one month) was few (5,
8.3%). Of the patients who reported the frequency of use
(67), Forty four (65.6%) were daily users. The patients
used two commonly available formulations, cigars and
the Madana Modakaya. The latter is a solid pulp of can-
nabis extract that can be chewed. However, these are
illicit cottage preparations and the concentrations of
chemical constituents (including that of tetrahydrocan-
nabinol) in this preparation have not been quantified.
Fifty nine patients smoked cannabis (57.3%), 21 (20.4%)
chewed the Madana Modakaya and 23 (22.3%) used both.
Eighteen (17.5%) cannabis users had a family history of a
psychiatric illness. Forty three patients (91.5%) started
using cannabis before the diagnosis of SSD. Only 3 (6.4%)
patients had started using it after the diagnosis of SSD.
Twenty four (23.3%) patients in the sample continued to
use cannabis after the initial presentation and all of them
had psychotic relapses during follow up.
On concurrent substance use, alcohol was the most fre-
quently used (54, 52.4%, missing data 1.9%) substance.
Nicotine use was also frequent and the formulations
included cigars, cigarettes and a local preparation called
'beedi'. Twenty one (20.4%, missing data: 12.6%) cannabis
users were using nicotine at time of presentation. Only
one person admitted to heroin use.
Comparison between SSD patients and non SSD patients in 
the LTC user group
As mentioned before, 47 (45.6%) patients in the LTC user
group were diagnosed with a SSD during the follow up.
Of the others (56, 54.3%), the diagnoses were as follows;
bipolar affective disorder (15, 14.6%), depression (5, 4.9%)
and alcohol withdrawal (2, 1.9%). Clinic records also
showed that 17(16.5%) patients (10 of them in their first
presentation) were diagnosed as CIP. In this group, 7
(41.2%) were diagnosed with SSD during follow up and
they were included in the SSD group. In the other ten, the
diagnosis remained as CIP. The diagnosis was unclear in
another 24 patients (23.3%).
There were no statistically significant differences
(assessed with chi square test and Fisher's exact test) in
the two groups with regard to age of presentation, marital
status, educational level, concurrent alcohol/nicotine use
and past consultation at a psychiatry clinic. However, the
LTC user SSD patients were more likely to have a positive
family history for a psychiatric disorder than non SSD
LTC users (RR - 3.1, 95% CI: 1.19 - 8.06). The chi square
value for this association was significant (table 4).
Comparison between patients diagnosed as CIP and other 
LTC users
Seventeen (16.5%) patients in the cannabis using group
were diagnosed as having CIP. On comparing the charac-
teristics of this subgroup with the rest of the LTC users,
Ethnicity
Sinhala 95 92.2
Tamil 6 5.8
Muslim 2 1.9
Concurrent substance use
Alcohol* 54 52.4
Nicotine* 21 20.4
Heroin 1 1.0
Other 0 0.0
Past history of a psychiatric consultation
Yes 42 40.8
No 61 59.2
Family history of a psychiatric disorder
Yes 18 17.5
No 85 82.5
*Data on alcohol use was missing in 2 patients and that of 
nicotine use was missing in 13 patients.
Table 1: Descriptive statistics of the socio-demographic variables 
of patients with life time cannabis (LTC) use (Continued)Rodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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having a past consultation at a psychiatry clinic was the
only significant finding (Table 4). There were no signifi-
cant associations (assessed with chi square test and
Fisher's exact test) for age of presentation, marital status,
educational level, concurrent alcohol/nicotine use, family
history of a psychiatric disorder, subsequent diagnosis of
SSD or bipolar affective disorder and compliance with
treatment (leaving against medical advice, attendance in
follow up clinics).
The mean duration of hospital stay for the CIP group
was 9.62 days [standard deviation (SD)-11.4, range 0-33]
and for the rest of LTC users it was 17.03 days (SD - 17.5,
range 0-107). This difference was not statistically signifi-
cant (unpaired t test; df-101, t-1.67, p = 0.097). Similarly,
the average number of psychotic relapses after the initial
admission was 1.62 for the CIP group (SD - 1.62, range 0-
6) and 2.01 (SD - 2.39, range 0 - 13) for other LTC users.
This was also not statistically significant (unpaired t test;
df-101, t-0.64, p = 0.521). We also compared the CIP
patients who had a past psychiatric consultation with
other CIP patients regarding the duration of hospital stay
and relapse rate. Again, there was no significant differ-
ence between the two groups (unpaired t test; p = 0.717
and 0.392 respectively).
Comparison between SSD patients in CIP group (CIP-SSD) 
and other LTC user SSD patients
This section compares the 7 patients diagnosed with SSD
after having an initial diagnosis of CIP with other SSD
patients in the LTC user group. The mean duration to
diagnosis of SSD since initial presentation was 36 months
[SD -41.28] for these 7 patients. The only significant dif-
ference between the two groups was that CIP-SSD
patients were more likely to have had a past consultation
at a psychiatry clinic (Table 4). The age and presence of
positive symptoms at admission did not show any differ-
ence between CIP-SSD and other LTC user-SSD patients.
In both groups, the mean duration of hospital stay was 16
days (SD - 16.8 and 14.3 for CIP-SSD and other LTC user-
SSD groups respectively).
Discussion
Prevalence of cannabis use
The prevalence of cannabis use in the general population
varies according to the acceptance of its use and legal
restrictions. The cultivation, use and sale of cannabis
(except for medicinal purposes) are illegal in Sri Lanka.
The population prevalence of cannabis use in Sri Lanka
as estimated by the National Dangerous Drugs Control
Board (NDDCB) was 3% in 2003[30]. The global average
for cannabis use in adult population is estimated to be
around 4%. However in many developed regions, the per-
centage is above the global average (Oceania -16%, North
America - 11%, and Western Europe - 7%)[31]. In our
sample which was a hospital based one with psychiatric
illnesses, the prevalence of life time use was 2.8%.
Substance abuse, and even alcohol use, is relatively less
among women in Sri Lanka, as it is not culturally accept-
able per gender norms. The consumption among females
contributes considerably to the prevalence of cannabis
Table 2: Number of patient records analyzed according to sex, cannabis use and presence of schizophrenia spectrum 
disorders (SSD) [total (n) - 3644]
Year Male Female (all NCU)
SSD present SSD absent SSD present SSD absent
LTC Users* NCU† LTC Users* NCU†
2004 16 44 12 312 38 296
2003 9 79 15 399 39 309
2002 6 61 7 400 48 312
2001 8 73 12 330 44 252
2000 8 55 10 239 48 163
Total 47 (1.3) 312 (8.6) 56 (1.5) 1680 (46.1) 217 (6.0) 1332 (36.6)
*LTCU -life time cannabis users, †NCU - Non cannabis users. The percentages are given within brackets in the totals rowRodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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use in populations of industrialized nations (where it has
been estimated) [8,32,33]. In our sample, the cannabis use
among females was nil. The very low prevalence of can-
nabis use in females may contribute to the overall low
prevalence in Sri Lanka. In addition, legal restrictions
may also limit the accessibility to the drug. However, it
should also be noted that the prevalence of substance use
is largely under-reported. Due to legal restrictions and
social norms, many patients do not reveal the use of can-
nabis (unfortunately, testing for cannabinoids in urine is
not performed in government hospitals due to the
expenses incurred).
Cannabis, SSD and gender
As mentioned previously, many studies published since
1987 have shown an association between cannabis use
and SSD[3]. At the same time, the current global epide-
miological data indicate that sex ratio of schizophrenia is
equal [34,35]. However it is interesting to note that in
many studies assessing the prevalence of SSD in sub-
stance abuse samples including that of cannabis, males
have significantly higher rates of SSD compared to
women. Regarding cannabis use, many of the published
studies are from industrialized nations. Still it is observed
that the number of female cannabis users is less com-
pared to male users (many studies report percentages
between 16% - 22% for females in their sam-
ples)[6,32,36,37]. Arendt et al[6] who followed up 535
patients treated for first episode psychosis report that
male sex and younger age to be risk factors in developing
subsequent SSD. It is interesting to note that among
females also, the cannabis users were more likely to be
diagnosed with SSD than non using females. Mauri et
al[37] who assessed the history of substance abuse in first
episode schizophrenia patients, report that 80% of the
sample had life time cannabis use. The number of male
substance abusing schizophrenic patients was signifi-
cantly more than the number of female patients. Similarly
Barnes et al[8] in a study of 152 first episode schizophre-
nia patients report lifetime substance abuse in 68% of the
sample. Cannabis was the most commonly used sub-
stance with 64.4% of the total sample having used it. In
the overall assessment, there were a greater proportion of
Table 3: The characteristics of cannabis use of patients 
admitting to life time cannabis use (n-103)
Variable Number Percentage (%)
Duration of use
1 day 3 2.9
1 week 2 1.9
1-4 weeks 0 0.0
1 - 6 months 11 10.7
7 -12 months 6 5.8
1 - 5 years 20 19.4
More than 5 years 18 17.5
Unknown 43 41.7
Frequency of use
Daily 44 42.7
more than once a week 2 1.9
About once a week 8 7.8
Less than once a week 9 8.7
First time 4 3.9
Unknown 36 35.0
Most recent use
Within 72 hours 41 39.8
3 -7 days 4 3.9
1 -4 weeks 2 1.9
1 -12 months 5 4.9
12 months ago 14 13.6
Unknown 37 35.9
Formulation of cannabis
Cigars 59 57.3
Madana modakaya 21 20.4
Both 23 22.3
Table 3: The characteristics of cannabis use of patients 
admitting to life time cannabis use (n-103) (Continued)Rodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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males in the substance abuse group compared to non
users (76.3% vs. 62%). In another study by Miller et al[38],
with 112 first episode schizophrenia patients, 34 admit-
ted to current/previous cannabis use and 30 of them were
males.
It is interesting that in almost all of the studies quoted
above, male cannabis users had higher rates for subse-
quent diagnosis of SSD. Yet, apart from Arendt et al[6]
other authors have not elaborated on this. Two studies
[8,37] have collectively analyzed all substance users
together in their gender analysis though cannabis was the
most used substance in both samples.
The absence of cannabis using females in our sample is
in contrast to many previously mentioned studies. It may
be questioned whether women/family would actually
reveal cannabis use to a medical doctor given the social
stigma involved especially when information gathering is
not anonymous. However, several large scale anonymous
data collections (by self report) support the observation
that substance use (tobacco and alcohol) is very low
among the general Sri Lankan female population [39-41].
The global health survey in 2003 estimates that the preva-
lence of smoking tobacco among females in Sri Lanka to
be 2.9%, while the same value for males was 39%[42]. The
same survey also showed that life time abstinence for
alcohol was 98.3% for women (66.5% for men)[41]. The
WHO GENACIS survey in 2002 also showed that a)
heavy and hazardous drinking, b) episodic heavy drinking
were not reported from females (0%) while the same per-
centages for men were 15.6% and 13.3% respectively[41].
These observations support our results of a zero self
reported cannabis use among females in this sample.
Population data of cannabis use among Sri Lankan
women is not available but indirect evidence comes from
the number of cannabis related arrests in 2003. Out of
9,556 cases, only 3% involved women[43]. 'Involvement'
Table 4: Comparison of patient subgroups within life time cannabis user group on demographic and clinical correlates
Variable †LTC user SSD**
patients (n-47) Vs
other LTC users (n-56)
CIP# patients (n-17) vs.
other LTC users (n-86)
CIP-SSD (n-7) patients
Vs. other SSD patients
in LTC user group (n-40)
Chi square value (degree of freedom - 1)
Age at presentation
(less than 30 years vs. more than 30 years)
0.254 0.113 1.422
Marital status 1.81 1.2 2.598
Level of education
(Secondary education vs. no secondary education)
0.4 0.15 3.065
Concurrent alcohol use 0.002 0.002 1.101
Concurrent nicotine use 0.615 0.0004 2.874
Past psychiatric consultation 0.546 4.22* 9.549*
Family history of a psychotic disorder 5.6* 0.0004 0.953
Subsequent diagnosis of SSD 0.163
Subsequent diagnosis of bipolar affective disorder 3.48
Leaving against medical advice 0.054 2.874 0.146
Attending follow up 3.841* 1.428 2.874
Statistical tests used are the chi square test and the Fisher's exact test, *p < 0.05, **SSD- Schizophrenia spectrum disorders, †LTC user - Life 
Time Cannabis user, #CIP-Cannabis induced psychosisRodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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does not necessarily mean consumption and some of
these arrests would have been due to drug possession
alone.
While assuredly other gender related and social factors
may play a role in this, there was nonetheless a statisti-
cally significant increase in the prevalence of SSD among
men (see above) in our sample. It also showed a strong
association between cannabis using males and SSD. The
absence of female cannabis users however, has an impact
on final conclusions. The logic in that regard is as follows;
1. Overall, in our sample, males were significantly 
more likely to be diagnosed with SSD than females
2. This finding is not in keeping with the global epide-
miological data of equal sex incidence of SSD
3. Cannabis use may be one risk factor for SSD in men 
as women didn't use it
4. This hypothesis is supported by the similar obser-
vations of previous studies cited above
However, what our study cannot exclude is that
whether cannabis using females are also at risk of SSD. In
fact Arendt et al[6] have indicated the possibility of that
being so. The data on relative risk for female cannabis
users to develop SSD is limited. Such a comparative anal-
ysis is warranted but needs to be carried out in a commu-
nity with both male and female users.
Association between cannabis and SSD
Three different hypotheses were mentioned earlier
regarding the association between cannabis use and
SSD[10].
1. Cannabis use causes SSD (causal model)
2. SSD patients are attracted to cannabis use (self 
medication hypothesis)
3. Cannabis use predisposes to SSD in a vulnerable 
minority
On the first theory, it is observed that only a few canna-
bis users develop SSD. In addition, the incidence of
schizophrenia has not increased despite an increase in
cannabis use worldwide[44]. Though many studies show
that cannabis use precedes SSD, there is no evidence to
say that cannabis use per se causes it [3,5,45]. In our sam-
ple only 8.1% of patients with SSD had a history of canna-
bis use and only 45.6% of cannabis users were diagnosed
with SSD during the follow up. Arendt et al have reported
a percentage of 44.5% in this regard in a similar study[6].
Regarding the second hypothesis, if psychosis prone
individuals are attracted to cannabis use, then it is likely
that SSD population has more cannabis users. Findings of
some studies support this theory [46-48] while others do
not[49,50]. Even in studies showing such an association,
the temporal relationship is unclear (which started first?).
Many demonstrate that cannabis use started before the
onset of SSD, but the evidence to contrary is lacking
[3,5,45]. Archie et al[32] have actually shown a reduction
in drug abuse in a follow up cohort with early interven-
tion. In our sample also, a larger proportion (91.5%) has
started using cannabis before the first admission (first
recorded episode of psychosis) compared to the 6.4%
starting use after the first admission. However 'first
admission' may not always be synonymous with 'onset of
disease'. It may also be possible that those in a prodrome
tried to self medicate themselves with cannabis and pre-
sented later. This cannot be clarified due to the retrospec-
tive nature of the study.
M a n y  r ec e n t  a d va n c e s  h a v e  bee n  m a d e  o n  t h e  t h i r d
hypothesis, where it is assumed that a third factor
increases the risk for SSD in some cannabis users. This
risk factor may be genetic, environmental or a combina-
tion of them. Studies on polymorphism of cannabinoid
receptor and of the gene encoding the catechol-O-methyl
transferase (COMT) enzyme have indicated a possible
genetic influence in this regard (see introduc-
tion)[11,51,19,52,53].
However, SSD is not purely a consequence of genetics.
The role of environmental factors in constituting a vul-
nerability to SSD with cannabis use is less explored (see
introduction). However, in our subgroup analysis (table
4), there was no difference between the groups on demo-
graphic or clinical correlates such as level of education,
concurrent substance use, civil status or family history of
a psychiatric illness. Having a family history of a psychiat-
ric disorder was significant in the sample when LTC using
SSD patients were compared to cannabis using non SSD
patients. However, this association is expected given the
genetic vulnerability to SSD. Alcohol and Nicotine were
the other substances of abuse consumed in this cohort.
However, this consumption also did not appear to be sig-
nificantly different between the subgroups studied. A
complete analysis based on the level of income, occupa-
tion and living conditions could not be carried out due to
incomplete data.
Cannabis induced psychosis (CIP); is it a 'true' diagnosis?
The diagnosis of CIP has been extensively debated. Many
authors are reluctant to accept such a diagnosis on the
premise that this 'psychosis' is in fact early onset schizo-
phrenia [27,28]. Still, some hold that such a diagnosis
exists[54]. What is consistently shown is that psychotic
episodes with cannabis are characterized by predomi-
nantly positive symptoms and occur at an earlier age. In
our sample, the majority of patients presented with posi-
tive symptoms (93.6%). Yet, we could not elicit any signif-
icant difference between those having a presentation of
CIP and others (or CIP-SSD patients and other LTC user
SSD patients) regarding age and positive symptoms.
On comparison of a) CIP patients with other LTC users
and b) CIP-SSD patients with other LTC using SSD
patients; having a past psychiatric consultation was sig-Rodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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nificantly more for the CIP and CIP-SSD patients. This
can be interpreted in two ways. One is that those who are
going to develop psychotic manifestations with cannabis
are likely to have some background vulnerability. On the
other hand it may be so that some of them were in a pro-
dromal stage of SSD to begin with and the onset of illness
predated the start of cannabis use. These two issues can-
not be reliably verified in a retrospective analysis.
We also could not observe a difference between CIP
patients and other LTC users with respect to the duration
of initial hospital admission or number of psychotic
relapses afterwards. While some authors have observed
that CIP patients without a previous psychiatric history
to recover faster[55,56], this could not be demonstrated
in our sample. However, the numbers in this sample were
small for a comprehensive analysis.
On follow up and compliance related matters, previous
studies have noted conflicting observations. Some
authors report no change in compliance compared to
those without cannabis use [32]. Two prospective studies
from cohorts in underprivileged communities in New
York, USA and Pakistan demonstrate less compliance
with treatment among the cannabis users [38,57]. In our
sample, loss to follow up was significantly less in LTC
u s e r  S S D  p a t i e n t s  w h e n  c o m p a r e d  t o  o t h e r  c a n n a b i s
users (table 4).
Policy on cannabis, is a total ban justified?
As mentioned previously, the cultivation, transport, sale
and use of cannabis is prohibited by law in Sri Lanka
except for medicinal purposes (mostly in oriental
Ayurvedic preparations). The prevalence of LTC use in
our sample was 2.8%. This was remarkably similar to the
estimated population prevalence of cannabis use (3% in
2003 with an estimated 600,000 users)[30]. Cannabis is
the only illegal drug that is cultivated within Sri Lanka
(mostly in rural areas). Almost all the cannabis inter-
cepted by law enforcement authorities are in the form of
unprocessed herb (73,714 kg in 2003)[30]. The small
amounts of Hashish or cannabis resin confiscated are
believed to be imported. Cannabis related arrests in the
time period concerned was 50 per 100,000 and was
increasing (29% increase in 2003 compared to 2002). In
2008, 71% of drug related arrests were due to canna-
bis[58].
The socio demographic pattern of cannabis use is
mainly rural and among men. The usual portrayal of can-
nabis is that of a 'poor man's' drug. Still, it is the cheapest
way to get 'drugged'. The 'Madana Modakaya' mentioned
previously is easily accessible to many school children
and adults and is sold for a paltry sum of Rs.5 (USD 0.05).
The average price of 1 kg of Cannabis herb in 2003 was
only USD15 (increased to USD 174 by 2008). Other nar-
cotics are considerably more expensive (Street price of 1
kg of opium was USD 5000 in 2003)[30]. The social
acceptance of cannabis may also have changed over time.
There is an increased glorification of cannabis use
('smoking pot') in media (movies, blogs, songs and social
networks) which may influence the young to try out can-
nabis[59].
To determine whether a total ban is justified, it is
important to examine the possible harms and benefits of
cannabis use. This has to be balanced against the possible
harms and benefits of a ban. There are two schools of
thought in this regard. The first is that cannabis use
should be legally prohibited as the risks outweigh the
benefits. The second view is that cannabis use should not
be prohibited. The basis for this argument stems from
one or many of the following assumptions;
1. banning would lead to more unlawful use
2. cannabis is a harmless or less harmful drug com-
pared to tobacco and alcohol
3. rather than a total ban, controlled use should be 
allowed
4. incarceration of mentally ill patients on drug 
related crimes may worsen their prognosis
5. legalization would lead to less stigma and more 
importantly it will avoid the unnecessary incarcera-
tion of the great majority that uses cannabis without 
long standing ill effects
Several countries that have lifted legal restrictions on
cannabis use (e.g. Mexico, Netherlands). However, none
of them have completely legalized cannabis. The term
that describes the legal status of cannabis in many of
these countries is 'decriminalization' or 'depenalization'
which refers to a reduction or non enforcement of laws
prohibiting cannabis use though it is not legally
accepted[60]. The legal status of cannabis is complex in
some countries where it's decriminalized. For example in
Netherlands, sale and possession of cannabis is illegal
while personal use is allowed[61]. 'Legalization' refers to a
more 'liberal' state where government may enforce some
restrictions on specific activities such as advertising and
sale, but largely 'accepts' the use of a drug (e.g. - legal sta-
tus of tobacco).
It is difficult to establish whether banning cannabis
would lead to increased illegal use. The overall low per-
centage of adult cannabis use (cf. tobacco and alcohol)
may be due to the legal ban in many countries and the
social stigma associated with it. On the other hand,
decriminalization has shown to increase the use of can-
nabis in several countries, though the causative role in
decriminalization is debated [60]. In Southern states of
Australia, cannabis consumption increased after penal-
ties were reduced in 1987 but this was not statistically sig-
nificant compared to other states where use was still
illegal[62]. Following decriminalization, cannabis use in
Netherlands increased steadily between 1984 and 1992.Rodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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In other European states and USA, where cannabis use
was illegal, the rates did not increase[60]. However after
1992, the rates increased in these countries too and it may
partly be attributable to the media influence and
increased drug trafficking. The experience in Mexico
shows that the area of cannabis cultivation in 2008 had
increased by a massive 35% compared to that of 2007[63].
The number of drug related arrests reached an all time
high in 2009 though it is not clear how many of these
were cannabis related. An increase in cannabis cultiva-
tion also affects neighbouring countries as some amount
of this harvest will be smuggled across the borders[63].
As mentioned above, another argument of proponents
for legalization is that cannabis is a harmless or a less
harmful drug compared to tobacco or alcohol. While it
may indeed be less harmful than tobacco and alcohol, the
notion that it is harmless is unacceptable. As mentioned
previously, the impact of cannabinoids on neurotransmit-
ter systems has been demonstrated experimentally. These
studies have also demonstrated many short term ill
effects of cannabis use such as mood changes, lapses in
judgment, short term memory loss and inducement of
positive and negative symptoms of schizophrenia. In
addition, there is strong epidemiological evidence includ-
ing that of this study, for an association between cannabis
use and SSD. In addition, the hospital based studies only
assess the full blown psychotic episodes associated with
cannabis use. The more subtle psychiatric manifestations
of long term cannabis use may go unnoticed in the popu-
lation but may contribute significantly to impaired per-
formance and cognition at an individual level. The
repeated findings of these experimental, biochemical,
epidemiological and genetic studies do not support the
view that cannabis is a harmless drug.
However the next question is, whether our response to
cannabis use is doing more harm than cannabis itself?
While the possibility remains that cannabis may predis-
pose to a long standing psychiatric illness such as schizo-
phrenia, it is also clear that only a few cannabis users are
affected to this extent and many use the drug without any
long standing ill effects. In our sample, of all cannabis
users, only 47 were diagnosed with SSD. This value is fur-
ther reduced when background risk for SSD is accounted
for (as calculated from SSD percentage in non cannabis
using patients).
One may argue whether a total ban is justified when
1. Only a small proportion of users are affected
2. A clear aetiological mechanism is yet to be demon-
strated
This issue brings forth one of the strongest arguments
of proponents for lifting a ban. In countries where canna-
bis use is totally prohibited as in Sri Lanka, cannabis
users; both healthy and mentally ill are imprisoned on
drug related charges. Ill effects of this can be assessed in
two ways.
Firstly, incarceration of mentally ill leads to a poor
patient outcome as the required standard of care includ-
ing proper treatment, rehabilitation and socializing
opportunities are denied to the patient. Though Sri Lanka
a s  m a n y  o t h e r  c o u n t r i e s,  h a v e  m e c h a n i s m s  t o  p r e v e n t
unnecessary incarceration of mentally ill individuals, they
are not foolproof. Even in United States it is estimated
that up to 12% of inmates are having mental health con-
cerns. Some argue that the figure may be even as high as
34% [64]. Despite the numbers being not available for Sri
Lankan jails, the strong possibility of mentally ill patients
needing inpatient psychiatric treatment being held at
prisons on cannabis related charges, have to be accepted.
Secondly, the negative aspect of a legal ban is very sig-
nificant when considering the impact on healthy individ-
uals (who may use cannabis without any long term ill
effects) imprisoned on cannabis related charges. As men-
tioned previously, the majority of drug related arrests in
Sri Lanka are due to cannabis. In USA, drug related
arrests reached a record high of 1.8 million in 2005. Mari-
juana offences accounted for 42.6% of it [65]. The ques-
tion here is, since those at risk of getting CIP or SSD with
cannabis are few, is it justified to incarcerate the vast
majority of people who may use cannabis without any
h a r m ? .  A s  m u c h  a s  m e n t a l  i l l n e s s  i s  a s s o c i a t e d  w i t h
stigma, imprisonment is also associated with similar
stigma. The ill effects on personal, family and social life
are also similar or worse. Hypothetically, if cannabis was
legalized, all these arrests and their negative impact
would be avoided.
On the other hand, one strong point for the opponents
for legalization is that, if a blanket ban is lifted, cannabis
use in Sri Lanka has all the right components to grow in
to a problematic drug use (It is locally grown, easily
accessible, cheap, glorified in the media plus a large can-
nabis naïve population including almost all the females).
It can be questioned whether testing the grounds by
legalizing a potentially harmful drug is warranted when
we are still trying to tackle the social, health and eco-
nomic problems of the already legalized tobacco and
alcohol.
We would not make an opinion on banning or legaliz-
ing cannabis on this paper. While our study shows that a
minority of cannabis users are at risk of SSD or CIP, it is
difficult to weigh it against the mass, non specific incar-
ceration of potentially healthy individuals (who might use
it without any ill effects) on cannabis related offences.
There are many loopholes in the current knowledge on
cannabis and its ill effects to make a firm opinion in this
regard.
What we do suggest therefore, is a more scientific
approach to the problem. The ideal situation would be to
identify those at risk of getting psychosis and discourage
use within this subgroup while avoiding unnecessary and
potentially harmful incarceration of healthy and mentallyRodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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ill patients on cannabis related charges. A good way for-
ward is to make a policy decision on a programme that
would address this issue comprehensively on scientific
evidence. Such a program should include;
1. monitoring the changing trends of cannabis use in 
the population
2. measuring the subtle psychiatric manifestations of 
cannabis use to accurately quantify the substance use 
burden
3. more funding for studies to identify vulnerability to 
cannabis related psychotic manifestations
4. counteracting the media glorification of cannabis 
use
5. curtailing local production of cannabis by educa-
tion and creating alternate employment opportunities 
to rural communities dependent on cannabis cultiva-
tion (rather than by punitive measures)
6. improving facilities of hospitals to provide testing 
for cannabinoids so that diagnosis can be confirmed 
for individuals and epidemiological data can be gath-
ered more accurately for the population
7. a mechanism to recommend necessary changes to 
legislature on the legal status of cannabis on the avail-
able valid scientific evidence
Limitations
Given the retrospective nature of the study, several limi-
tations have to be noted. The prevalence of cannabis use
among patients may be under-reported due to a) conceal-
ment by patient b) not being queried by the interviewer c)
inability to test for urinary cannabinoids in government
hospitals and d) loss of records. Many clinically relevant
variables such as family income, occupation, past medical
history, living circumstances could not be analyzed prop-
erly due to incomplete records. Though cannabis use was
exclusive to males in this sample, it is also possible that
females with cannabis use were overlooked due to con-
cealment by the patient or failure to elicit a proper history
by the interviewer.
There were few other undiagnosed patients with psy-
chotic episodes where the presentation was circumstan-
tially linked to cannabis use. We looked at three factors to
establish a link in this regard; duration of cannabis use
less than 6 months before the first admission; more than
once weekly use and use within last 72 hours of admis-
sion. On these criteria, a further 16 (15.5%) patients had
their symptoms circumstantially linked to cannabis. This
group was not included in the analysis as the confounding
factors for such a presentation cannot be established
from records alone.
The diagnostic criterion used in many studies quoted in
text is the diagnostic and statistics manual (DSM - IV).
However psychiatric morbidities in Sri Lankan hospitals
are diagnosed with ICD - 10. This may have an impact on
head to head comparisons of our results and others. For
example, a diagnosis of schizophrenia requires a mini-
m u m  p e r i o d  o f  6  m o n t h s  w i t h  s y m p t o m s  i n  D S M  I V
while it is just one month in ICD 10. This may result in a
larger number of formal diagnoses with ICD 10.
As discussed previously, difficulty in identifying the
actual onset of symptoms/illness by retrospective exami-
nation is also a limitation of the study. It should be further
noted that though all males and females admitted and/or
consulted in clinics during the period of study were com-
pared with each other with respect to SSD, these two
groups may not be matched with relation to age, family
history, co morbidities and other confounding factors.
Conclusions
In this retrospective cohort with psychiatric illnesses,
male sex and LTC use were significant risk factors for
SSD. Majority had used cannabis before the diagnosis of
SSD. However we could not identify a particular sub-
group of users that are at increased risk to recommend
targeted primary prophylaxis. However, this vulnerable
group may be over represented in populations with
already diagnosed psychiatric morbidity and therefore
cannabis use may be discouraged in such groups.
In our opinion, further research on cannabis use in Sri
Lanka can develop in three overlapping spheres.
Firstly, there is the need for hospital based studies on
psychiatrically ill populations to clarify several issues that
we could not address given the retrospective nature of
our study. These include; the establishment of timeline
between start of symptoms and cannabis use (to exclude
start of use during a prodrome), use of laboratory confir-
mation of recent cannabis use to improve accuracy of
data, correlating symptom severity with the amount of
herbal cannabis consumed, exploring a family history of
SSD and cannabis use to identify a genetic vulnerability
for both behaviours and assessing efficacy of different
pharmacological therapies to treat CIP or SSD following
cannabis use. These issues can be addressed by prospec-
tive cohort studies or by randomized controlled clinical
trials (with regard to efficacy of pharmacological thera-
pies).
Secondly, it is important to conduct community based
studies to assess the prevalence of cannabis use and sub-
tle psychiatric morbidity of this use that may not present
to hospitals for treatment. One possibility is to follow up
a large birth cohort and see the impact over the years.
Needless to say it is a very costly and arduous exercise.
Another possibility is to identify 'psychosis prone' indi-
viduals through screening tools and follow up such
cohorts. Both types of studies can be found in literature
but has not been conducted in populations of developing
nations where the social dynamics are different.Rodrigo et al. Substance Abuse Treatment, Prevention, and Policy 2010, 5:16
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Thirdly, there is the need for more experimental and
empirical laboratory studies for purposes of quantifying
the cannabinoid compounds in herbal cannabis and in
local preparations as 'madana modakaya'. As mentioned
previously, the cocktail of chemicals in herbal cannabis
contain chemicals with contrasting effects. The relative
concentrations of each may also contribute to the nature
of observed symptoms and their severity.
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